*All times shown in EST

9:00 am Online Registration & Virtual Coffee

9:15 am Chair’s Opening Remarks

Examining the Potential of Engineered Treg Cells For the Modulation of Antigen Specific Responses

9:30 am Treg-based Therapies to Induce Immune Tolerance in Transplantation & Autoimmunity


  • Lessons learned from Treg-directed therapies in liver transplantation (polyclonal Tregs vs low dose IL-2 therapy)
  • Engineered Tregs for the modulation of antigen-specific responses
  • Quell Therapeutics strategy to enhance Treg therapies

10:00 am Engineered Treg Products for Neurodegenerative Diseases


  • Inflammation in the central nervous system (CNS) is the common thread in all neurodegenerative diseases (NDD)
  •  Tregs dampen inflammation and promote regeneration in the CNS
  •  Universal donor CAR- Tregs are cell drug products for a wide range of NDD

10:30 am Engineered Tregs as a Therapeutic Modality


  • Scalable technology to generate robust phenotype of engineered Tregs is critically needed to address many autoimmune and antiinflammatory disorders
  • TCR and CAR antigen specific Tregs enable optimal efficacy and safety
    of engineered Tregs

11:00 am Virtual Speed Networking & Morning Break

Driving Knowledge of Treg Cell Biology to Supercharge Development of Treg Directed Therapies

12:00 pm Panel Discussion: Exploring Key Questions to Advance Understanding of Treg Behaviour


  • Highlighting the importance of exploring the relevant mechanisms of action to further understanding of Treg cell biology and behaviour
  • Exploring the importance of the origin of the Treg cells and viability of the starting material
  • What are the different small molecules or antibodies we can use to target T regs for enhanced immune tolerance?

12:30 pm Antigen Specificity of Tumor Infiltrating Tregs


  • Expansion of Tregs is seen in various human cancers and therapies directed at ablating them show efficacy.
  • Use of scRNAseq with paired TCR seq used to identify Treg TCRs that are enriched in the tumor microenvironment.
  • Multiple approaches were then used to identify the antigen specificity of tumor infiltrating Tregs.

1:00 pm Lunch & Networking

2:00 pm Small Molecules to Promote Treg Function in Transplantation & Autoimmunity

  • Wayne Hancock Professor of Pathology & Laboratory Medicine and Chief of the Division of Transplant Immunology, Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine


  •  Small molecules are available that increase Treg numbers and/or suppressive function
  • These can be alone or in conjunction with other agents to promote allograft acceptance and control autoimmunity

2:30 pm PT101, an IL-2 Mutein for Selectively Activating & Expanding Treg

  • Jo Viney Co-Founder, President & CSO , Pandion Therapeutics


  • Discovery of PT101, an IL-2 mutein
  • Selective activation and expansion of Tregs
  • Translation of model systems to human studies

3:00 pm Afternoon Refreshments & Poster Session

Hearing Clinical Trial Case Studies to Discover How Treg Directed Therapies Are Being Successfully Implemented in the Clinic

4:00 pm Corelates of Biological & Clinical Response to Low-dose Interleukin-2 in Patients with Systemic Lupus Erythematosus: Results from a Phase-II Proof of Concept Trial


  • Outline of LUPIL-2, a Phase II Proof of Concept study evaluating ILT-101 in moderate to severe SLE patients
  • Chronic SC administration of ILT-101 is well tolerated
  • ILT-101 treatment clinically improves moderate to severe SLE patients
  • Clinical improvement correlates with Treg stimulation
  • Early Treg activation predicts clinical outcome

4:30 pm Hearing insights on a Clinical Program for IL2 Treg Directed Therapy

5:00 pm Treg Cell Therapy in Hematopoietic Stem Cell Transplantation to Reduce Graft-Versus-Host Disease & Improve Engraftment

  • Everett Meyer Assistant Professor , Stanford University School of Medicine


  • Phase 2 trial results with Treg engineered donor grafts show reduced acute and chronic graft versus host disease (GVHD) incidence compared to standard of care.
  • Treg cells appear to improve donor bone marrow engraftment in preclinical studies which is being tested clinically in a phase 1 trial in the setting combined kidney and hematopoietic stem cell transplantation.
  • Preclinical strategies to improve Treg cell function show promise in GVHD prevention, GVHD treatment and in inducing immune tolerance in combined organ and hematopoietic stem cell transplantation studies.

5:30 pm Chair’s Closing Remarks & Close of Day 1